Device development for cardiovascular therapeutics: Concepts and regulatory implications: Concepts and regulatory implications

Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease: Fourth Edition

Volumn , Issue , 2012, Pages 41-52

  Schoen, Frederick J ^a   Zuckerman, Bram D ^b   Farb, Andrew ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902550177     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0101-8.00003-5     Document Type: Chapter

References (41)

1. Daemen J, Serruys PW Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same?. Circulation 2007, 116:316-328.
2. Chaikoff EL The development of prosthetic heart valves-lessons in form and function. N Engl J Med 2007, 357:1368-1371.
3. Rahimtoola SH Choice of prosthetic heart valve for adult patients: an update. J Am Coll Cardiol 2010, 55:2413-2426.
4. Ye J, Cheumg A, Lichtenstein SV, et al. Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. J Thorac Cardiovasc Surg 2009, 137:167-173.
5. Joyce LD, Noon GP, Joyce DL, DeBakey ME Mechanical circulatory support-a historical review. ASAIO J. 2004, 50:10-12.
6. DiMarco JP Implantable cardioverter-defibrillators. N Engl J Med 2003, 349:1836-1847.
7. Greenhalgh RM, Powell JT Endovascular repair of abdominal aortic aneurysm. N Engl J Med 2008, 358:494-501.
8. Scott EC, Glickman MH Conduits for hemodialysis access. Semin Vasc Surg 2007, 20:158-163.
9. Pietsch JB, Shluzas LA, Pate-Cornell, et al. Stage-gate process for the development of medical devices. J Med Dev 2009, 30:2104-1-02104-16.
10. Zenios S, Makower J, Yock P Biodesign: the process of innovating medical technologies 2010, Cambridge University Press, Cambridge, UK.
11. Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical innovation. Lancet 2009, 374:1097-1104.
12. Muni NI, Zuckerman BD The process of regulatory review for new cardiovascular devices. Cardiovascular therapeutics: a companion to Braunwald's heart disease 2007, 67-75. Saunders Elsevier, Philadelphia. 3rd ed. E.M. Antman (Ed.).
13. Li H, Yue LQ Statistical and regulatory issues in nonrandomized medical device clinical studies. J Biopharm Stat 2008, 18:20-30.
14. Muni NI, Ho C, Mallis EJ Regulatory issues for computerized electrocardiographic devices. J Electrocardiol 2004, 37:74-77.
15. U.S.Department of Health and Human Services, U.S.Food and Drug Administration, Center for Devices and Radiological Health CDRH FY 2004 annual report June 24, Available at. http://www.fda.gov/cdrh/annual/fy2004.
16. Sapirstein W, Zuckerman B, Dillard J FDA approval of coronary artery brachytherapy. N Engl J Med 2001, 344:297-299.
17. Kramer DB, Mallis E, Zuckerman BD, et al. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Therapeut 2010, 17:2-7.
18. Grunkemeier GL, Starr A, Rahimtoola SH Prosthetic heart valve performance: long-term follow-up. Curr Probl Cardiol 1992, 17:329-406.
19. Wheatley DJ Clinical evaluation: statistical considerations and how to meet them in clinical practice. J Heart Valve Dis 2004, 13:S11-S13.
20. Grunkemeier GL, Johnson DM, Naftel DC Sample size requirements for evaluating heart valves with constant risk events. J Heart Valve Dis 1994, 3:53-58.
21. Grunkemeier GL, Payne N, Jin R, et al. Propensity score analysis of stroke after off-pump coronary artery bypass grafting. Ann Thorac Surg 2002, 74:301-305.
22. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
23. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231.
24. Fleming TR Surrogate endpoints and FDA's accelerated approval process. Health Affairs 2011, 24:67-78.
25. DeGruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Controlled Clin Trials 2001, 22:485-502.
26. Dembitsky WP, Tector AJ, Park S, et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg 2004, 78:2123-2129.
27. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011, 364:1718-1727.
28. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000, 36:1152-1158.
29. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010, 363:1597-1607.
30. U.S.Food and Drug Administration Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees Available at. http://www.fda.gov/cber/gdlns/clindatmon.htm.
31. Goodman GR Medical device error. Crit Care Nurs Clin North Am 2002, 14:407-416.
32. Carthey J, de Leval MR, Reason JT The human factor in cardiac surgery: errors and near misses in a high technology medical domain. Ann Thorac Surg 2001, 72:300-305.
33. Reason J Human error: models and management. Br Med J 2000, 320:768-770.
34. Anderson JM, Schoen FJ, Brown SA, Merritt K Implant retrieval and evaluation. Biomaterials science: an introduction to materials in medicine 2004, 771-782. Saunders Elsevier, Philadelphia. 2nd ed. B.D. Ratner, A.S. Hoffman, F.J. Schoen, J.E. Lemons (Eds.).
35. Schoen FJ, Hoffman AS Implant and device failure. Biomaterials science: an introduction to materials in medicine 2004, 760-765. Saunders Elsevier, Philadelphia. 2nd ed. B.D. Ratner, A.S. Hoffman, F.J. Schoen, J.E. Lemons (Eds.).
36. Baretich MF Medical device incident investigation. Biomed Sci Instrum 2007, 43:302-305.
37. Shepherd M SMDA '90 (Safe Medical Devices Act of 1990): user facility requirements of the final medical device reporting regulation. J Clin Eng 1996, 21:114-148.
38. Yoganathan AP, Corcoran WH, Harrison EC, Carl JR The Bjork-Shiley aortic prosthesis: flow characteristics, thrombus formation and tissue overgrowth. Circulation 1978, 58:70-76.
39. Walker AM, Funch DP, Sulsky SI, Dreyer NA Patient factors associated with strut fracture in Bjork-Shiley 60 convexo-concave heart valves. Circulation 1995, 92:3235-3239.
40. Blot WJ, Ibrahim MA, Ivey TD, et al. Twenty-five-year experience with the Björk-Shiley Convexoconcave heart valve: a continuing clinical concern. Circulation 2006, iii:2850-2857.
41. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study: a prospective multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010, 160:1035-1041.